Literature DB >> 9255160

Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects.

M Ichise1, H Golan, J R Ballinger, D Vines, A Blackman, H Moldofsky.   

Abstract

UNLABELLED: The aim of this study was to evaluate the in vivo stability of ECD brain SPECT.
METHODS: Twenty normal volunteers (35.4 +/- 9.1 yr) each had six ECD scans at 30, 60, 120, 240, 360 and 480 min postinjection. Each scan was acquired for 24 min using a triple-head SPECT system. Average counts per pixel were measured from frontal, temporal, parietal, occipital, cerebellum, basal ganglia, thalamus and white matter regions. ECD clearance rates were calculated by fitting regional time activity data to a monoexponential equation. Regional gray-to-white matter (G/W) and gray-to-cerebellum (G/C) ratios were calculated for each scan. Analysis of variance was used to compare regional ECD clearance and ratio measurements.
RESULTS: The average ECD clearance was 4.3%/hr. There was a significant regional variation in the ECD clearance, being higher for occipital (6.34%/hr) but lower for both white matter (2.39%/hr) and thalamus (2.45%/hr). Both G/W and G/C ratios showed a significant regional variation with time. The overall G/W ratio was 2.13 at 30 min and became progressively lower after 2 hr, reaching 1.78 at 8 hr. All regional G/W ratios declined with time except for thalamus where it remained constant at 2.15. The overall G/C ratio was 0.984 at 30 min but it declined after 4 hr, reaching 0.955 at 8 hr. All regional G/C ratios declined with time except for thalamus where it increased progressively from 0.955 to 1.120 at 8 hr.
CONCLUSION: ECD clears from normal brain slowly and shows a significant regional variation. As a result, G/W contrast begins to decrease after 2 hr and the gray-matter activity pattern becomes significantly different after 4 hr. Therefore, the optimal imaging time may be between 30-120 min. However, images obtained up to 4 hr still maintain the initial gray-matter activity pattern.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255160

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  99mTc-HMPAO and 99mTc-ECD perform differently in typically hypoperfused areas in Alzheimer's disease.

Authors:  Pierre Malick Koulibaly; Flavio Nobili; Octave Migneco; Paolo Vitali; Philippe H Robert; Nicola Girtler; Jacques Darcourt; Guido Rodriguez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-15       Impact factor: 9.236

2.  Required time delay from 99mTc-HMPAO injection to SPECT data acquisition: healthy subjects and patients with rCBF pattern.

Authors:  Gerda Thomsen; Robin de Nijs; Esben Hogh-Rasmussen; Vibe Frokjaer; Claus Svarer; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-10       Impact factor: 9.236

3.  White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition.

Authors:  Val J Lowe; Emily S Lundt; Matthew L Senjem; Christopher G Schwarz; Hoon-Ki Min; Scott A Przybelski; Kejal Kantarci; David Knopman; Ronald C Petersen; Clifford R Jack
Journal:  J Nucl Med       Date:  2018-04-19       Impact factor: 10.057

4.  A Novel method of seizure onset zone localization by serial Tc-99 m ECD brain perfusion SPECT clearance patterns.

Authors:  Chanan Sukprakun; Chusak Limotai; Kitiwat Khamwan; Panya Pasawang; Supatporn Tepmongkol
Journal:  Brain Imaging Behav       Date:  2022-02-23       Impact factor: 3.224

5.  Comparison of 11C-Pittsburgh Compound B and 18F-Flutemetamol White Matter Binding in PET.

Authors:  Burcu Zeydan; Christopher G Schwarz; Scott A Przybelski; Timothy G Lesnick; Walter K Kremers; Matthew L Senjem; Orhun H Kantarci; Paul H Min; Bradley J Kemp; Clifford R Jack; Kejal Kantarci; Val J Lowe
Journal:  J Nucl Med       Date:  2021-12-16       Impact factor: 11.082

6.  Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans.

Authors:  Jenna M Sullivan; Keunpoong Lim; David Labaree; Shu-Fei Lin; Timothy J McCarthy; John P Seibyl; Gilles Tamagnan; Yiyun Huang; Richard E Carson; Yu-Shin Ding; Evan D Morris
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

7.  Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.

Authors:  Victor L Villemagne; William E Klunk; Chester A Mathis; Christopher C Rowe; David J Brooks; Bradley T Hyman; Milos D Ikonomovic; Kenji Ishii; Clifford R Jack; William J Jagust; Keith A Johnson; Robert A Koeppe; Val J Lowe; Colin L Masters; Thomas J Montine; John C Morris; Agneta Nordberg; Ronald C Petersen; Eric M Reiman; Dennis J Selkoe; Reisa A Sperling; Koen Van Laere; Michael W Weiner; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

8.  Neuropsychological Correlates of Brain Perfusion SPECT in Patients with Macrophagic Myofasciitis.

Authors:  Axel Van Der Gucht; Mehdi Aoun Sebaiti; Emmanuel Itti; Jessie Aouizerate; Eva Evangelista; Julia Chalaye; Romain K Gherardi; Nilusha Ragunathan-Thangarajah; Anne-Catherine Bachoud-Levi; François-Jérôme Authier
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

9.  Investigation of white matter PiB uptake as a marker of white matter integrity.

Authors:  Burcu Zeydan; Christopher G Schwarz; Val J Lowe; Robert I Reid; Scott A Przybelski; Timothy G Lesnick; Walter K Kremers; Matthew L Senjem; Jeffrey L Gunter; Hoon-Ki Min; Prashanthi Vemuri; David S Knopman; Ronald C Petersen; Clifford R Jack; Orhun H Kantarci; Kejal Kantarci
Journal:  Ann Clin Transl Neurol       Date:  2019-03-03       Impact factor: 4.511

10.  Evaluation of the difference-correction effect of the gamma camera systems used by easy Z-score Imaging System (eZIS) analysis.

Authors:  Yasushi Yamamoto; Masahisa Onoguchi; Kazunori Kawakami; Masuo Haramoto; Rei Wake; Jun Horiguchi; Hajime Kitagaki
Journal:  Ann Nucl Med       Date:  2014-01-25       Impact factor: 2.668

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.